(Q37929504)

25 August 2017

1 reference

title

Review of current guidelines on the care of postherpetic neuralgia (English)

1 reference

25 August 2017

Charles E Argoff

1

1 reference

25 August 2017

language of work or name

English

0 references

publication date

1 September 2011

1 reference

25 August 2017

published in

Postgraduate Medicine

1 reference

25 August 2017

volume

123

1 reference

25 August 2017

issue

5

1 reference

25 August 2017

page(s)

134-142

1 reference

Herpes zoster (shingles) and postherpetic neuralgia

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

The incidence of herpes zoster in a United States administrative database

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

A case of human immunodeficiency virus infection initially presented with disseminated herpes zoster

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Treatment of postherpetic neuralgia: a review of therapeutic options

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Pain and its persistence in herpes zoster

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Mechanism-based pain diagnosis: issues for analgesic drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Transcriptional and posttranslational plasticity and the generation of inflammatory pain

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Mechanistic Stratification of Antineuralgic Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Pharmacologic management of neuropathic pain: evidence-based recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Recommendations for the pharmacological management of neuropathic pain: an overview and literature update

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Vaccination against Herpes Zoster and Postherpetic Neuralgia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Analgesic therapy in postherpetic neuralgia: a quantitative systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Algorithm for neuropathic pain treatment: an evidence based proposal.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Antidepressants in the treatment of neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Cyclic antidepressants and the risk of sudden cardiac death

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

A randomized, double-blind, placebo-controlled trial of a glycine antagonist in neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Amitriptyline, but not lorazepam, relieves postherpetic neuralgia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

A cross-sectional cohort survey in 2100 patients with painful diabetic neuropathy and postherpetic neuralgia: Differences in demographic data and sensory symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Topical 5% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: results of a double-blind, placebo-controlled, multinational efficacy and safety trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Post-herpetic neuralgia: 5% lidocaine medicated plaster, pregabalin, or a combination of both? A randomized, open, clinical effectiveness study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Efficacy and safety of 5% lidocaine (lignocaine) medicated plaster in comparison with pregabalin in patients with postherpetic neuralgia and diabetic polyneuropathy: interim analysis from an open-label, two-stage adaptive, randomized, controlled tri

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes zoster

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Pharmacokinetic analysis of capsaicin after topical administration of a high-concentration capsaicin patch to patients with peripheral neuropathic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Systematic review of topical capsaicin for the treatment of chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patients with peripheral neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Morphine, gabapentin, or their combination for neuropathic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Subcutaneous injection of botulinum toxin a is beneficial in postherpetic neuralgia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

A focused review on the use of botulinum toxins for neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Evidence-based interventional pain medicine according to clinical diagnoses. 17. Herpes zoster and post-herpetic neuralgia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

The effectiveness of repetitive paravertebral injections with local anesthetics and steroids for the prevention of postherpetic neuralgia in patients with acute herpes zoster

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

The PINE study of epidural steroids and local anaesthetics to prevent postherpetic neuralgia: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Intrathecal methylprednisolone for intractable postherpetic neuralgia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Use of a lidocaine patch in the management of postsurgical neuropathic pain in patients with cancer: a phase III double-blind crossover study (N01CB).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Spinal cord stimulation in postherpetic neuralgia and in acute herpes zoster pain

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

Relief of post-herpetic neuralgia by surgical removal of painful skin: 5 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2469

21 January 2018

Identifiers

DOI

10.3810/PGM.2011.09.2469

1 reference

25 August 2017

1 reference